605results about How to "Reduce apoptosis" patented technology

Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.

The present invention relates to novel quinoxaline, quinazoline and phthalazine derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in treating and preventing neurodegenerative diseases.

The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

The present invention provides methods and direct cardiac contact diastolic recoil device to improve diastolic recoil of a heart and includes a biocompatible film attached to or enclosing one or more structural elements that store elastic energy during heart contraction and release energy during heart filling.

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.

The application provides novel complexes of Cbl-b polypeptides and Cbl-b-associated proteins. The application also provides methods and compositions for treating Cbl-b-associated diseases such as viral disorders.

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.

As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.

The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5", and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.

The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice in vivo.

The invention relates to a separation and efficient amplification culture method for an antigen specific T lymphocyte. By means of the immunomagnetic bead technology and the character of an active T cell expression CD137, the antigen specific T lymphocyte is separated from a complex cell mass; then an antigen specific T lymphocyte with high tumor killing activity is obtained through in-vitro efficient amplification culture. CD137L (CD137-ligand), IL-7, IL-15 and IL-2 are added in the culturing process, so that the phenomenon that activated and induced cells are liable to apoptosis in the culturing process is avoided, the amplification time is increased, and the killing activity of the antigen specific T lymphocyte is improved.

The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-δ and should be useful for treating conditions mediated by the same.

The invention provides an umbilical cord tissue cryopreservation and resuscitation method. The method comprises the following steps: S1, cutting umbilical cord tissues to obtain first tissue strips; S2, immersing the first tissue strips in a vitrification solution, and then directly cryopreserving the first tissue strips to obtain second tissue strips; and S3, resuscitating the second tissue strips to obtain third tissue strips, wherein the vitrification solution includes a first vitrification solution, a second vitrification solution and a third vitrification solution, and the step S2 includes the following processes: sequentially immersing the first tissue strips in the first vitrification solution, the second vitrification solution and the third vitrification solution, transferring thefirst tissue strips into liquid nitrogen, and cryopreserving the first tissue strips to obtain the second tissue strips. The umbilical cord strips are cryopreserved and resuscitated through a vitrification technology, so the operation time is shortened, the cryopreservation efficiency is improved, and the necrosis rate of the umbilical cord tissues in the cryopreservation and resuscitation processis reduced.

The invention relates to a drinking type acidulant and a preparation method and application thereof. Each 100ml of the acidulant contains components of 15-25ml of formic acid, 25-35ml of lactic acid,15-25g of citric acid, 5-15g of fumaric acid, 1-8g of calcium formate, 1-8g of sodium butyrate and the balance deionized water, wherein all of the components are 100ml. The preparation method comprises the following steps of performing injection according to the amount of 50-80% of the total amount of water to a stirring tank, starting a power supply, performing stirring at 120r/min, slowly addingthe fumaric acid, then adding the calcium formate and the sodium butyrate, performing stirring for 15min, after the fumaric acid, the calcium formate and the sodium butyrate sufficiently dissolve inthe water, slowly adding the citric acid, the lactic acid and the formic acid separately, and finally, adding the remaining water for uniform stirring so as to obtain products. Compared with the priorart, the drinking type acidulant contains various organic acid and organic acid salts, can regulate the acid of a ration system, can reduce the pH value of the digestive tracts of animals, can improve the activity of digestive enzymes, can promote the digestion of nutrient substances, can effectively control diarrhoea of piggies at the weaning and child care period, can regulate the intestinal microecology balanced, and can promote growth of the piggies at the weaning and child care period. Besides, when the drinking type acidulant is drunk, growth and propagation of pathogenic microorganismsin animal organisms, feeds and environment can be greatly reduced, and the usage amount of antibiotics can be directly reduced, so that drug tolerance, remaining and pollution problems caused by antibiotics can be reduced.

The invention relates to a cosmetic and/or pharmaceutical composition comprising, in a physiologically suitable medium, a carob peptide extract (Ceratonia siliqua L.) as an active agent for promoting aquaporin expression. The present invention also relates to the use of a carob peptide extract (Ceratonia siliqua L.), as an active agent for promoting aquaporin expression, in a cosmetic composition for improving the moisturization and the barrier function of the epidermis and for stimulating skin regeneration. The invention also relates to the use of this novel active agent for preparing a pharmaceutical, in particular dermatological, composition for regulating and/or stimulating aquaporin activity. The invention also relates to a cosmetic treatment method for preventing or combating dryness of the skin and mucous membranes and the manifestations of skin aging.

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.

The invention discloses application of neoflavonoids compounds Hip B and Hip C. The neoflavonoids compounds Hip B and Hip C are prepared according to the following steps: eluting seabuckthorn seed meal extractum through an MCI gel column, and then performing semi-preparation separation through a C18 chromatographic column, a diol chromatographic column and a C18 chromatographic column to obtain the neoflavonoids compounds Hip B and Hip C. Activity research is carried out on the compounds Hip B and Hip C to verify that the compounds Hip B and Hip C can reduce the contents of lactate dehydrogenase and NO in myocardial cells, and delay apoptosis of the myocardial cells by reducing the protein expression levels of Bcl-2 and Bax in the cells, and can be used for preparing drugs for preventing or treating myocardial injury related diseases. The invention also provides application of Hip B and Hip C in preparation of products with neuroprotection and/or nerve repair effects; and it is verified that the compounds Hip B and Hip C can improve nerve synapse atrophy and reduce excessive phosphorylation of tau protein, and can be used for preparing drugs for preventing or treating neurodegenerative diseases.